Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

Figure 3 Waterfall plots of percentage change in tumor burden from baseline (n = 190). The “y” axis represents the percentage change in tumor burden from baseline by treatment. The immune-related adverse events are distinguished by different colors. Negative/positive values represent maximum tumor reduction or minimum tumor increase, respectively. A: 91 patients had progressive disease; B: 99 patients achieved complete response, partial response, or stable disease. irAE: Immune-related adverse event.